Changes (Δ) in total life expectancy and CHD/stroke-free life expectancy with statin therapy, compared with predicted 10-y total CVD mortality risk for different risk factor profiles.

Hypertension is defined as either reporting use of antihypertensive medication or having a systolic blood pressure ≥160 mm Hg or a diastolic blood pressure ≥95 mm Hg; diabetes is defined as either reporting use of antidiabetic medication or having a serum glucose level ≥11.0 mmol/l. Predictions for lifetime CHD/stroke incidence, CHD/stroke mortality, and total CVD mortality for these risk profiles, are shown in the Table S2.Conventional conversion factors: to convert HDL and total cholesterol to milligrams per deciliter, divide by 0.0259; creatinine to milligrams per deciliter, divide by 88.4; glucose to milligrams per deciliter, divide by 0.0555.aThe gain in total life expectancy in years can be computed as follows: 0.2632−0.0077×age (in years)+0.0138×[1 if male sex, 0 if not]−0.0115×[1 if current cigarette smoker, 0 if not]+0.0023×systolic blood pressure (in mm Hg)−0.0018×diastolic blood pressure (in mm Hg)+0.0479×[1 if hypertension, 0 if not]+0.0548×total cholesterol (in mmol/l)−0.1448×HDL cholesterol (in mmol/l)−0.0218×[1 if diabetes mellitus, 0 if not]+0.0086×serum glucose (in mmol/l)+0.0099×body mass index (in kg/m2)−0.3989×waist-to-hip ratio+0.0025×serum creatinine (in µmol/l).bThe gain in CHD/stroke-life expectancy in years can be computed as follows: 1.8854−0.0330×age (in years)+0.0470×[1 if male sex, 0 if not]+0.0049×systolic blood pressure (in mm Hg)−0.0040×diastolic blood pressure (in mm Hg)+0.1157×total cholesterol (in mmol/l)−0.3605×HDL cholesterol (in mmol/l)−0.0899×[1 if diabetes mellitus, 0 if not]+0.0049×serum glucose (in mmol/l)+0.0175×body mass index (in kg/m2)−0.2915×waist-to-hip ratio+0.0023×serum creatinine (in µmol/l).BMI, body mass index; WHR, waist-to-hip ratio.